- Home
- TWIN vs AGEN Comparison
TWIN vs AGEN Comparison
Compare TWIN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWIN
- AGEN
- Stock Information
- Founded
- TWIN 1918
- AGEN 1994
- Country
- TWIN United States
- AGEN United States
- Employees
- TWIN N/A
- AGEN N/A
- Industry
- TWIN Industrial Machinery/Components
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TWIN Industrials
- AGEN Health Care
- Exchange
- TWIN Nasdaq
- AGEN Nasdaq
- Market Cap
- TWIN 186.2M
- AGEN 142.8M
- IPO Year
- TWIN N/A
- AGEN 2000
- Fundamental
- Price
- TWIN $13.99
- AGEN $3.95
- Analyst Decision
- TWIN Strong Buy
- AGEN Buy
- Analyst Count
- TWIN 1
- AGEN 2
- Target Price
- TWIN $12.00
- AGEN $14.50
- AVG Volume (30 Days)
- TWIN 43.5K
- AGEN 459.5K
- Earning Date
- TWIN 11-05-2025
- AGEN 11-11-2025
- Dividend Yield
- TWIN 1.14%
- AGEN N/A
- EPS Growth
- TWIN N/A
- AGEN N/A
- EPS
- TWIN N/A
- AGEN N/A
- Revenue
- TWIN $340,738,000.00
- AGEN $101,706,000.00
- Revenue This Year
- TWIN $10.79
- AGEN $60.49
- Revenue Next Year
- TWIN $8.43
- AGEN N/A
- P/E Ratio
- TWIN N/A
- AGEN N/A
- Revenue Growth
- TWIN 15.46
- AGEN N/A
- 52 Week Low
- TWIN $6.16
- AGEN $1.38
- 52 Week High
- TWIN $14.93
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- TWIN 63.65
- AGEN 37.47
- Support Level
- TWIN $13.06
- AGEN $4.26
- Resistance Level
- TWIN $14.93
- AGEN $4.80
- Average True Range (ATR)
- TWIN 0.72
- AGEN 0.33
- MACD
- TWIN -0.09
- AGEN -0.04
- Stochastic Oscillator
- TWIN 56.07
- AGEN 11.97
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).